Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC.

J Pharmacol Exp Ther. 2001 Feb;296(2):558-66.

PMID:
11160644
2.

The human prostanoid DP receptor stimulates mucin secretion in LS174T cells.

Wright DH, Ford-Hutchinson AW, Chadee K, Metters KM.

Br J Pharmacol. 2000 Dec;131(8):1537-45.

3.

A random rapid equilibrium mechanism for leukotriene C4 synthase.

Gupta N, Greeser MJ, Ford-Hutchinson AW.

Adv Exp Med Biol. 1999;469:327-32.

PMID:
10667349
4.

A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.

Wright DH, Nantel F, Metters KM, Ford-Hutchinson AW.

Eur J Pharmacol. 1999 Jul 14;377(1):101-15.

PMID:
10448933
5.

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al.

J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.

PMID:
10411562
6.

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8.

PMID:
10406640
7.

Characterization of the human cysteinyl leukotriene CysLT1 receptor.

Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, Austin CP, Chateauneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams DL Jr, Ford-Hutchinson AW, Caskey CT, Evans JF.

Nature. 1999 Jun 24;399(6738):789-93.

PMID:
10391245
8.

Demonstration of cell-specific phosphorylation of LTC4 synthase.

Gupta N, Nicholson DW, Ford-Hutchinson AW.

FEBS Lett. 1999 Apr 16;449(1):66-70.

9.
10.

Kinetic mechanism of glutathione conjugation to leukotriene A4 by leukotriene C4 synthase.

Gupta N, Gresser MJ, Ford-Hutchinson AW.

Biochim Biophys Acta. 1998 Mar 30;1391(2):157-68.

PMID:
9554994
11.

Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.

Wright DH, Metters KM, Abramovitz M, Ford-Hutchinson AW.

Br J Pharmacol. 1998 Apr;123(7):1317-24.

12.

Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.

Gupta N, Nicholson DW, Ford-Hutchinson AW.

Can J Physiol Pharmacol. 1997 Oct-Nov;75(10-11):1212-9.

PMID:
9431445
13.

Characterization of microsomal GST-II by western blot and identification of a novel LTC4 isomer.

Jakobsson PJ, Scoggan KA, Yergey J, Mancini JA, Ford-Hutchinson AW.

J Lipid Mediat Cell Signal. 1997 Sep;17(1):15-9.

PMID:
9302651
14.

Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities.

Jakobsson PJ, Mancini JA, Riendeau D, Ford-Hutchinson AW.

J Biol Chem. 1997 Sep 5;272(36):22934-9.

15.

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.

Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC, et al.

Br J Pharmacol. 1997 May;121(1):105-17.

16.

Production of leukotriene C4 in different human tissues is attributable to distinct membrane bound biosynthetic enzymes.

Scoggan KA, Jakobsson PJ, Ford-Hutchinson AW.

J Biol Chem. 1997 Apr 11;272(15):10182-7.

17.

Regulation of the biosynthesis of the sulphido-leukotrienes.

Ford-Hutchinson AW.

Adv Exp Med Biol. 1997;400B:841-7. Review. No abstract available.

PMID:
9547637
19.
20.

Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives.

Li CS, Black WC, Chan CC, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay D, Kargman S, Lau CK, Mancini J, et al.

J Med Chem. 1995 Dec 8;38(25):4897-905.

PMID:
8523403
21.

Epitope-labeled soluble human interleukin-5 (IL-5) receptors. Affinity cross-link labeling, IL-5 binding, and biological activity.

Brown PM, Tagari P, Rowan KR, Yu VL, O'Neill GP, Middaugh CR, Sanyal G, Ford-Hutchinson AW, Nicholson DW.

J Biol Chem. 1995 Dec 8;270(49):29236-43.

23.

Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.

Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Penneton M, et al.

J Pharmacol Exp Ther. 1995 Sep;274(3):1531-7.

PMID:
7562530
24.

Characterization of arachidonic-acid-metabolizing enzymes in adult Schistisoma mansoni.

Abdel Baset H, O'Neill GP, Ford-Hutchinson AW.

Mol Biochem Parasitol. 1995 Jul;73(1-2):31-41.

PMID:
8577345
25.

Effect of altitude on urinary leukotriene (LT) E4 excretion and airway responsiveness to histamine in children with atopic asthma.

Christie PE, Yntema JL, Tagari P, Ysselstijn H, Ford-Hutchinson AW, Lee TH.

Eur Respir J. 1995 Mar;8(3):357-63.

26.

Antiasthmatic effects of a leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs.

Becker AB, Black C, Lilley MK, Bajwa K, Ford-Hutchinson AW, Simons FE, Tagari P.

J Appl Physiol (1985). 1995 Feb;78(2):615-22.

PMID:
7759431
27.

Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist.

Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, Ford-Hutchinson AW, Gauthier JY, Lord A, Masson P, et al.

Can J Physiol Pharmacol. 1995 Feb;73(2):191-201. Erratum in: Can J Physiol Pharmacol 1995 Jun;73(6):747.

PMID:
7621356
28.

Renal leukotriene C4 synthase: characterization, partial purification and alterations in experimental glomerulonephritis.

Petric R, Nicholson DW, Ford-Hutchinson AW.

Biochim Biophys Acta. 1995 Jan 20;1254(2):207-15.

PMID:
7827126
29.

Leukotriene antagonists and inhibitors: clinical applications.

Ford-Hutchinson AW.

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:69-74. Review. No abstract available.

PMID:
7732907
30.

Characterization of human LTC4 synthase.

Ali A, Nicholson DW, Ford-Hutchinson AW.

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:171-3. No abstract available.

PMID:
7732828
31.

Regulation of leukotriene biosynthesis.

Ford-Hutchinson AW.

Cancer Metastasis Rev. 1994 Dec;13(3-4):257-67. Review.

PMID:
7712588
32.

Leukotriene C4 synthase and 5-lipoxygenase activating protein. Regulators of the biosynthesis of sulfido-leukotrienes.

Ford-Hutchinson AW.

Ann N Y Acad Sci. 1994 Nov 15;744:78-83. Review. No abstract available.

PMID:
7825864
33.

Elevated cysteinyl leukotriene excretion in experimental glomerulonephritis.

Petric R, Ford-Hutchinson AW.

Kidney Int. 1994 Nov;46(5):1322-9.

35.

Increased urinary LTE4 excretion following inhalation of LTC4 and LTE4 in asthmatic subjects.

Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, Schmitz-Schumann M, Lee TH.

Eur Respir J. 1994 May;7(5):907-13.

36.

5-Lipoxygenase.

Ford-Hutchinson AW, Gresser M, Young RN.

Annu Rev Biochem. 1994;63:383-417. Review. No abstract available.

PMID:
7979243
37.

5-Lipoxygenase activating protein and leukotriene C4 synthase: therapeutic targets for inhibiting the leukotriene cascade.

Ford-Hutchinson AW.

Adv Prostaglandin Thromboxane Leukot Res. 1994;22:13-21. Review. No abstract available.

PMID:
7771328
38.

Chronic leukotriene inhibition in the rat fails to modify the toxicological effects of a cyclooxygenase inhibitor.

Ford-Hutchinson AW, Tagari P, Ching SV, Anderson CA, Coleman JB, Peter CP.

Can J Physiol Pharmacol. 1993 Oct-Nov;71(10-11):806-10.

PMID:
8143238
39.

Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues.

O'Neill GP, Ford-Hutchinson AW.

FEBS Lett. 1993 Sep 13;330(2):156-60.

40.

A rapid biochemical method for measuring antigen-induced pulmonary eosinophil margination in allergic guinea pigs.

Tagari P, Black C, Marshall S, Ford-Hutchinson AW.

J Immunol Methods. 1993 Jul 6;163(1):49-58.

PMID:
8335959
41.

Purification to homogeneity and the N-terminal sequence of human leukotriene C4 synthase: a homodimeric glutathione S-transferase composed of 18-kDa subunits.

Nicholson DW, Ali A, Vaillancourt JP, Calaycay JR, Mumford RA, Zamboni RJ, Ford-Hutchinson AW.

Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2015-9.

42.

Photoaffinity labelling of human leukotriene C4 synthase in THP-1 cell membranes.

Ali A, Zamboni RJ, Ford-Hutchinson AW, Nicholson DW.

FEBS Lett. 1993 Feb 15;317(3):195-201.

43.

Activation of human eosinophils and differentiated HL-60 cells by interleukin-5.

Tagari P, Pecheur EI, Scheid M, Brown P, Ford-Hutchinson AW, Nicholson D.

Int Arch Allergy Immunol. 1993;101(3):227-33.

PMID:
8391887
44.

Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions.

Ford-Hutchinson AW.

Springer Semin Immunopathol. 1993;15(1):37-50. Review. No abstract available.

PMID:
8362342
45.

5-Lipoxygenase activation in psoriasis: a dead issue?

Ford-Hutchinson AW.

Skin Pharmacol. 1993;6(4):292-7. Review.

PMID:
8198815
46.

Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects.

Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, Schmitz-Schumann M, Lee TH.

Am Rev Respir Dis. 1992 Dec;146(6):1531-4.

PMID:
1333741
47.

Quantitation of eosinophil Major Basic Protein cytotoxicity to rodent respiratory epithelium.

Tagari P, Chee P, Chan C, McKee K, Black C, Nicholson D, Ford-Hutchinson AW.

Agents Actions. 1992 Nov;37(3-4):171-3.

PMID:
1295362
48.

Purification of human leukotriene C4 synthase from dimethylsulfoxide-differentiated U937 cells.

Nicholson DW, Klemba MW, Rasper DM, Metters KM, Zamboni RJ, Ford-Hutchinson AW.

Eur J Biochem. 1992 Oct 15;209(2):725-34.

49.

Human leukotriene C4 synthase expression in dimethyl sulfoxide-differentiated U937 cells.

Nicholson DW, Ali A, Klemba MW, Munday NA, Zamboni RJ, Ford-Hutchinson AW.

J Biol Chem. 1992 Sep 5;267(25):17849-57.

50.

BQ-153, a novel endothelin (ET)A antagonist, attenuates the renal vascular effects of endothelin-1.

Cirino M, Motz C, Maw J, Ford-Hutchinson AW, Yano M.

J Pharm Pharmacol. 1992 Sep;44(9):782-5.

PMID:
1360536

Supplemental Content

Loading ...
Support Center